Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Immunic MS asset misses primary goal of midstage trial
IMU-838 showed only “modest benefit” over placebo at improving the yearly rate of percent brain volume change in patients with progressive MS.
Darren Incorvaia
Apr 30, 2025 3:05pm
Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3
Apr 28, 2025 7:25am
ALX Oncology doubles down as lead asset fails 2 phase 2 trials
Apr 25, 2025 2:25pm
Large trial reveals link between lowered BP and dementia risk
Apr 24, 2025 11:33am
Sanofi's oral TNF asset misses mark in phase 2 psoriasis trial
Apr 24, 2025 4:46am
Ascletis sees no benefit to high, fast oral GLP-1 dose titration
Apr 23, 2025 7:25am
